Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia.

Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia. Abstract Text:

Kristine Mace Erlandson,Junfeng Sun,Peter C Iwen,Mark E Rupp,Kristine Mace Erlandson,Junfeng Sun,Peter C Iwen,Mark E Rupp,

Background. @nbsp; The impact of antibiotic resistance on the clinical outcome of patients with vancomycin-resistant Enterococcus (VRE) bacteremia remains unclear. There are limited data comparing patient outcomes during the early era of vancomycin resistance with the period of more-potent antibiotic availability. Methods. @nbsp; A retrospective review was conducted of 113 patients with VRE bacteremia at a single institution from August 1993 to September 2005. Patients were assigned to a group on the basis of initial antibiotic choice for treatment of VRE (linezolid, quinupristin-dalfopristin, or combinations of other agents, before newer options were available). Outcome measurements were examined for the initial episode of VRE bacteremia, and multiple logistic regression analysis was performed to compare group outcomes. Results. @nbsp; Overall mortality was 37.2% (42 of 113 patients). VRE bacteremia caused or significantly contributed to death in 29 (69%) of 42 patients. Seventy-one patients were initially treated with linezolid, 20 with quinupristin-dalfopristin, and 22 with combinations of other agents. Univariate analysis indicated significantly more deaths in the quinupristin-dalfopristin group (odds ratio, 5.45; 95% confidence interval, 1.89-15.9) and in the other-agents group (odds ratio, 2.94; 95% confidence interval, 1.09-7.94) than in the linezolid group. However, after adjustment for severity of illness, treatment group was not a significant independent factor. Conclusion. @nbsp; Despite the development of antimicrobial agents with greater potency against VRE, a significant change in clinical outcome was not observed. This suggests that vancomycin resistance does not significantly influence mortality and points to the continued need for prospective, randomized clinical trials.

Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia. Publishing Authors By Initials

KM Erlandson,J Sun,PC Iwen,ME Rupp,KM Erlandson,J Sun,PC Iwen,ME Rupp,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical infectious diseases : an official publica

VOLUME: 46

Page Numbers: 30-6

Journal Abbreviation: Clin. Infect. Dis.

ISSN: 1537-6591

DAY: 1

MONTH: Jan

YEAR: 2008

Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9203213

Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia.

AFFILIATION: Departments of 1Internal Medicine, 2Preventive and Societal Medicine, and 3Pathology and Microbiology, University of Nebraska Medical Center, Omaha.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Infect Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia Related Publications

• Auditory temporal resolution in children assessed by magnetoencephalography.
• Automated robotic harvesting of protein crystals-addressing a critical bottleneck or instrumentation overkill?
• Candida albicans Sun41p, a Putative Glycosidase, Is Involved in Morphogenesis, Cell Wall Biogenesis, and Biofilm Formation.
• Clinical neurology.
• Dendroscope: An interactive viewer for large phylogenetic trees.
• Determination of deoxynivalenol in whole wheat flour and wheat bran.
• Effect of induction of parturition on immunoglobulin content of colostrum and calf serum.
• Effect of reconstruction beam polarization on the kinetics of anisotropic gratings in bacteriorhodopsin.
• Effects of 5-fluorouracil on the adrenals of normal and tumor-bearing rats.
• Endoscopic management of pancreatic pseudocysts.
• Human Crossveinless-2 is a novel inhibitor of bone morphogenetic proteins.
• Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia.
• Interactions of the fungal pathogen Candida albicans with the host.
• Latency effect of the pitch response due to variations of frequency and spectral envelope.
• Light-induced extinction originating from holographic scattering.
• Metastatic tumors of the central nervous system.
• Not perfect-just among the best available: reply.
• Psychopathology of patients treated early for phenylketonuria: results of the German collaborative study of phenylketonuria.
• Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
• Semirealistic models of the cochlea.
• The economic consequences of not treating depression.
• Trends in research on the aging nervous system.
• Unintentional wrong-sided peripheral nerve block.
• [Acoustic trauma and military service (author's transl)]
• [Activity of the sympathetic nervous system during experimentally induced hypoxemia in man (author's transl)]
• [Current nomenclature of the periodontal tissues and their diseases]
• [Hydergine therapy of pregnancy toxemia.]
• [Natural course of venous drainage insufficiency in pelvic and leg deep vein thrombosis]
• [Neurogenic bladder.]
• [Not Available.]